CommercialCoverageLow impact
07.03.23h, Autonomic Nervous System Testing
Independence Blue Cross·Neurology, Endocrinology, Internal Medicine +2 more·Medical Policy
Effective date
Jun 16, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued its Autonomic Nervous System (ANS) Testing policy effective 06/16/2025, maintaining coverage for medically necessary diagnostic and clinical decision-making ANS testing while continuing to exclude noninvasive portable automated devices (ANSAR ANX 3.0, SUDOSCAN, ESC) as experimental/investigational. The BILLING REQUIREMENT header was removed from the policy, but coverage criteria and covered CPT codes (95921, 95922, 95923) remain unchanged.
Action Required
No immediate action required. This is a policy reissue confirming the Company's continuing position with no substantive changes to coverage criteria or billing requirements. Billing teams should note: (1) Continue billing CPT codes 95921, 95922, 95923 for laboratory-based ANS testing when medical necessity criteria are met; (2) Continue denying claims for noninvasive portable automated ANS devices (ANSAR ANX 3.0, SUDOSCAN, ESC) as experimental/investigational; (3) Ensure prior claim denials for these excluded devices remain in effect. Update internal policy references from the previous 07.03.23h version to this 03/04/2026 reissue for documentation purposes.